Study S000719

A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02081118
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 209
Start: 2014-02
Primary completion: 2015-03
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Type 2 Diabetes
Interventions: DRUG:HM11260C; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Change in baseline in glycosylated haemoglobin (HbA1c) at 16 weeks [Up to day 155]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009733	Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. Del Prato S, Diabetes, obesity & metabolism	2020	Randomized trial	PMID 32128957 DOI	cites ClinicalTrials.gov:NCT02081118